Seroquel - PI
... Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1)]. SEROQUEL is not approved for the treatment of patients with dementia-relat ...
... Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1)]. SEROQUEL is not approved for the treatment of patients with dementia-relat ...
Colchicine for pericarditis: hype or hope? REVIEW Massimo Imazio , Antonio Brucato
... was found. In the recently published open-label clinical trial (COPE), colchicine, as adjunct to conventional treatment, significantly decreased the subsequent recurrence rate (actuarial rates at 18 months were, respectively, 10.7 vs. 32.3%, P ¼ 0.004; NNT ¼ 5.0) and symptoms persistence at 72 h (re ...
... was found. In the recently published open-label clinical trial (COPE), colchicine, as adjunct to conventional treatment, significantly decreased the subsequent recurrence rate (actuarial rates at 18 months were, respectively, 10.7 vs. 32.3%, P ¼ 0.004; NNT ¼ 5.0) and symptoms persistence at 72 h (re ...
Pr VIAGRA*
... Patients should stop taking PDE5 inhibitors, including VIAGRA, and consult their physician immediately if they experience a decrease in, or sudden loss of, vision in one or both eyes. Postmarketing reports of sudden loss of vision have occurred rarely, in temporal association with the use of PDE5 in ...
... Patients should stop taking PDE5 inhibitors, including VIAGRA, and consult their physician immediately if they experience a decrease in, or sudden loss of, vision in one or both eyes. Postmarketing reports of sudden loss of vision have occurred rarely, in temporal association with the use of PDE5 in ...
SEROQUEL (quetiapine fumarate) TABLETS HIGHLIGHTS OF PRESCRIBING INFORMATION
... Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain (5.5) • Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, ...
... Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain (5.5) • Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, ...
Magnesium Sulfate In 5% Dextrose Injection, USP
... without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. CONTRAINDICATIONS: Intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery. WA ...
... without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. CONTRAINDICATIONS: Intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery. WA ...
Dabigatran etexilate for the prevention of stroke in patients with
... dosed at 110 mg twice-daily was noninferior to warfarin for the prevention of stroke, but had a lower risk of bleeding. There are few commercially available assays to monitor the effects of dabigatran and there is no known antidote that can complicate the management of emergent bleeding. For selecte ...
... dosed at 110 mg twice-daily was noninferior to warfarin for the prevention of stroke, but had a lower risk of bleeding. There are few commercially available assays to monitor the effects of dabigatran and there is no known antidote that can complicate the management of emergent bleeding. For selecte ...
PK/PD - Physiologie et Thérapeutique Ecole Véto Toulouse (ENVT)
... • However, they also predict that when the AM half-life is short, the best predictor is always T>MIC and when the half-life is long, the best predictor is always AUC/MIC whatever the antibiotic. • These kind of results are very important for veterinary medicine that uses many long-acting formulation ...
... • However, they also predict that when the AM half-life is short, the best predictor is always T>MIC and when the half-life is long, the best predictor is always AUC/MIC whatever the antibiotic. • These kind of results are very important for veterinary medicine that uses many long-acting formulation ...
447 kB - Propofol
... • Is propofol safe for procedural sedation in children? A prospective evaluation of propofol versus ketamine in ...
... • Is propofol safe for procedural sedation in children? A prospective evaluation of propofol versus ketamine in ...
MetroCream
... lotion) preparations are particularly effective against the inf1ammatory, papulopustular component of rosacea. The mechanisms by which topical metronidazole acts in reducing inflammatory lesions of rosacea are unknown, but may include an anti-bacterial and/or an antiinflammatory effect (see Detailed ...
... lotion) preparations are particularly effective against the inf1ammatory, papulopustular component of rosacea. The mechanisms by which topical metronidazole acts in reducing inflammatory lesions of rosacea are unknown, but may include an anti-bacterial and/or an antiinflammatory effect (see Detailed ...
AusPAR: Armodafinil - Therapeutic Goods Administration
... Product Information The approved Product Information (PI) current at the time this AusPAR was prepared can be found as Attachment 1. For the most recent PI, please refer to the TGA website at.
...
... Product Information The approved Product Information (PI) current at the time this AusPAR was prepared can be found as Attachment 1. For the most recent PI, please refer to the TGA website at
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
... the patient agrees, the dosage may be reduced gradually to a lower maintenance dose; in some favourable cases, treatment may be discontinued. The availability of the sublingual tablet in doses of 2 mg and 8 mg allows for a downward titration of dosage. For patients who may require a lower buprenorph ...
... the patient agrees, the dosage may be reduced gradually to a lower maintenance dose; in some favourable cases, treatment may be discontinued. The availability of the sublingual tablet in doses of 2 mg and 8 mg allows for a downward titration of dosage. For patients who may require a lower buprenorph ...
Seroquel - PI
... Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1)]. SEROQUEL is not approved for the treatment of patients with dementia-relat ...
... Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1)]. SEROQUEL is not approved for the treatment of patients with dementia-relat ...
HIGHLIGHTS OF PRESCRIBING INFORMATION
... Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. DUAC Gel should be used with caution in patients receiving such agents. ...
... Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. DUAC Gel should be used with caution in patients receiving such agents. ...
1 EC-NAPROSYN (naproxen delayed
... Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater ...
... Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater ...
product monograph - Eli Lilly Canada
... in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include 1) immediate discontinuation of all antipsychotic drugs including ZYPREXA and other drugs not essential to therapy; 2) i ...
... in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include 1) immediate discontinuation of all antipsychotic drugs including ZYPREXA and other drugs not essential to therapy; 2) i ...
STALEVO (carbidopa, levodopa and entacapone)
... Dyskinesia (involuntary movements) may occur or be exacerbated at lower dosages and sooner with Stalevo than with preparations containing only carbidopa and levodopa. The occurrence of dyskinesias may require dosage reduction. In pivotal trials, the treatment difference incidence of dyskinesia was 1 ...
... Dyskinesia (involuntary movements) may occur or be exacerbated at lower dosages and sooner with Stalevo than with preparations containing only carbidopa and levodopa. The occurrence of dyskinesias may require dosage reduction. In pivotal trials, the treatment difference incidence of dyskinesia was 1 ...
magnesium sulfate in water for injection
... convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. CONTRAINDICATIONS Intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hour ...
... convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. CONTRAINDICATIONS Intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hour ...
oxycodone controlled release tablets
... The usual starting dose for opioid-naïve patients or patients presenting with severe pain uncontrolled by weaker opioids is 10 mg 12-hourly, or 5 mg 12-hourly for patients with renal or hepatic impairment. The dose should then be carefully titrated, as frequently as once a day if necessary, to achie ...
... The usual starting dose for opioid-naïve patients or patients presenting with severe pain uncontrolled by weaker opioids is 10 mg 12-hourly, or 5 mg 12-hourly for patients with renal or hepatic impairment. The dose should then be carefully titrated, as frequently as once a day if necessary, to achie ...
APO–KETOCONAZOLE
... who are expected to be on prolonged therapy (>2 weeks) or who have a history of significant alcohol consumption. The concurrent use of ketoconazole with potentially hepatotoxic drugs should be most carefully monitored, especially in patients who are expected to be on prolonged therapy or who have a ...
... who are expected to be on prolonged therapy (>2 weeks) or who have a history of significant alcohol consumption. The concurrent use of ketoconazole with potentially hepatotoxic drugs should be most carefully monitored, especially in patients who are expected to be on prolonged therapy or who have a ...
metronidazole
... lithium has been reported to increase serum lithium concentrations, resulting in signs of lithium toxicity in several patients. Serum lithium and serum creatinine levels should be obtained several days after commencing metronidazole therapy to detect any increase that may precede clinical symptoms o ...
... lithium has been reported to increase serum lithium concentrations, resulting in signs of lithium toxicity in several patients. Serum lithium and serum creatinine levels should be obtained several days after commencing metronidazole therapy to detect any increase that may precede clinical symptoms o ...
Why Do We Use 600 mg of Rifampicin in
... [35]. Whether raising these concentrations in the bacterium and at the site of infection by application of higher rifampicin doses actually improves killing of the bacteria and, ultimately, treatment outcome remains to be investigated. Thus, the current dose of rifampicin used in internationally rec ...
... [35]. Whether raising these concentrations in the bacterium and at the site of infection by application of higher rifampicin doses actually improves killing of the bacteria and, ultimately, treatment outcome remains to be investigated. Thus, the current dose of rifampicin used in internationally rec ...
Activated Charcoal - Paramedic Advantage
... outlined scope of practice within individual jurisdictions for specific medication administration guidelines. ...
... outlined scope of practice within individual jurisdictions for specific medication administration guidelines. ...
Use of Codeine in Children
... False – there is little evidence to confirm that the side effects of codeine are significantly fewer or less severe than other opioids when used at equipotent doses. Purported benefits of lower incidence of CNS and respiratory depression have been noted after single doses of codeine although they ...
... False – there is little evidence to confirm that the side effects of codeine are significantly fewer or less severe than other opioids when used at equipotent doses. Purported benefits of lower incidence of CNS and respiratory depression have been noted after single doses of codeine although they ...
Australian public assessment for Enzalutamide
... Following submission, the product received marketing approval in the US, EU, Japan and South Korea, amongst a number of countries. Product information The approved Product Information (PI) current at the time this AusPAR was prepared can be found as Attachment 1. For the most recent PI, please refer ...
... Following submission, the product received marketing approval in the US, EU, Japan and South Korea, amongst a number of countries. Product information The approved Product Information (PI) current at the time this AusPAR was prepared can be found as Attachment 1. For the most recent PI, please refer ...
ARE STATINS NEPHROPROTECTIVE?:A DOSE DEPENDENT STUDY IN ALBINO RATS Research Article
... nephritis and crystallization of the antibiotics within the renal tubule. Although in most instances the mechanism mediating nephrotoxicity are unclear, susceptibility of the kidney to toxic injury appears to be related at least in part, due to the complexities of renal anatomy and physiology [2]. R ...
... nephritis and crystallization of the antibiotics within the renal tubule. Although in most instances the mechanism mediating nephrotoxicity are unclear, susceptibility of the kidney to toxic injury appears to be related at least in part, due to the complexities of renal anatomy and physiology [2]. R ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.